The Anticancer Role of Omega-3 Polyunsaturated Fatty Acids was Closely Associated with the Increase in Genomic DNA Hydroxymethylation

Author(s): Qionglin Huang, Mingming Mo, Yu Zhong, Qingjin Yang, Junjie Zhang, Xiaoxia Ye, Lijian Zhang, Chun Cai*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) have significant multiple antitumor roles. However, whether epigenetic DNA hydroxymethylation enrolls in the anticancer process of omega- 3 PUFAs is still not clear yet.

Objective: To expound the interaction between the anti-tumor role of omega-3 PUFAs and the DNA demethylation pathway and thus provide a firm foundation for deepening our understanding on anticancer mechanism of omega-3 PUFAs.

Methods: Colorectal Cancer (CRC) model rats were induced to generate tumor by N-methyl-N-nitrosourea and their counterparts treated with omega-3 PUFAs during the induction. The blood samples from different treatment groups of rats [Normal Control group (NC), colorectal cancer model group (CRC) and omega-3 PUFAs Medication Group (MG)] were used as experimental materials. Genomic 5-hydroxymethylocytosine (5hmC) content was quantified using LC-MS/MS, and the expression of ten-eleven translocation dioxygenase 1 (TET1), catalyzing the generation of 5hmC, was also evaluated by quantitative real-time PCR.

Results: We observed lower tumor incidence and small tumor size in MG group when compared with CRC group, supporting the effective anticancer role of omega-3 PUFAs. Due to the formation of CRC, 5hmC level was dramatically dropped in CRC group when compared with the NC group. Notably, 5hmC percentage in MG group remarkably increased close to NC group and was significantly higher than that in the CRC group. Consistent alteration pattern of TET1 expressions in mRNA was also observed in the tested groups of rats.

Conclusion: The anticancer effect of omega-3 PUFAs was positively correlated with global 5hmC accumulation and TET1 expression, suggesting DNA hydroxymethylation pathway was factually involved in the anticancer process of omega-3 PUFAs.

Keywords: Omega-3 polyunsaturated fatty acids, ten-eleven translocation dioxygenase, 1, 5-hydroxymethylcytosine, DNA hydroxymethylation, colorectal cancer, cancer model group.

Jing, K.; Wu, T.; Lim, K. Omega-3 polyunsaturated fatty acids and cancer. Anticancer. Agents Med. Chem., 2013, 13, 1162-1177.
Bhangle, S.; Kolasinski, S.L. Fish oil in rheumatic diseases. Rheum. Dis. Clin. North Am., 2011, 37, 77-84.
Swedberg, K. n-3 Fatty acids in cardiovascular disease. N. Engl. J. Med., 2011, 365, 1159.
D’Archivio, M.; Scazzocchio, B.; Vari, R.; Santangelo, C.; Giovannini, C.; Masella, R. Recent evidence on the role of dietary PUFAs in cancer development and prevention. Curr. Med. Chem., 2017, 25(16), 1818-1836.
Torres, C.; Diaz, A.M.; Principe, D.R.; Grippo, P.J. The complexity of omega-3 fatty acids modulation of signaling pathways related to pancreatic cancer. Curr. Med. Chem., 2017, 25(22), 2608-2623.
Akagi, D.; Hoshina, K.; Watanabe, T.; Conte, M.S. Drug therapy for abdominal aortic aneurysms utilizing omega-3 unsaturated fatty acids and their derivatives. Curr. Drug Targets, 2018, 19(11), 1309-1317.
Rahman, M.; Beg, S.; Ahmad, M.Z.; Kazmi, I.; Ahmed, A.; Rahman, Z.; Ahmad, F.J.; Akhter, S. Omega-3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery. Curr. Drug Targets, 2013, 14, 708-722.
Park, J.M.; Kwon, S.H.; Han, Y.M.; Hahm, K.B.; Kim, E.H. Omega-3 polyunsaturated Fatty acids as potential chemo-preventive agent for gastrointestinal cancer. J. Canc Prev., 2013, 18, 201-208.
Laviano, A.; Rianda, S.; Molfino, A.; Rossi, F.F. Omega-3 fatty acids in cancer. Curr. Opin. Clin. Nutr. Metab. Care, 2013, 16, 156-161.
Huang, Q.; Wen, J.; Chen, G.; Ge, M.; Gao, Y.; Ye, X.; Liu, C.; Cai, C. Omega-3 polyunsaturated fatty acids inhibited tumor growth via preventing the decrease of genomic DNA methylation in colorectal cancer rats. Nutr. Canc, 2016, 68, 113-119.
Cho, Y.; Turner, N.D.; Davidson, L.A.; Chapkin, R.S.; Carroll, R.J.; Lupton, J.R. Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation. Exp. Biol. Med. (Maywood), 2014, 239, 302-310.
Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 2011, 333, 1300-1303.
He, Y.F.; Li, B.Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; Sun, Y.; Li, X.; Dai, Q.; Song, C.X.; Zhang, K.; He, C.; Xu, G.L. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science, 2011, 333, 1303-1307.
Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; Rao, A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 2009, 324, 930-935.
Yang, Q.; Wu, K.; Ji, M.; Jin, W.; He, N.; Shi, B.; Hou, P. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J. Biomed. Nanotechnol., 2013, 9, 1607-1616.
Liu, C.; Liu, L.; Chen, X.; Shen, J.; Shan, J.; Xu, Y.; Yang, Z.; Wu, L.; Xia, F.; Bie, P.; Cui, Y.; Bian, X.W.; Qian, C. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One, 2013, 8e62828
Zhang, L.; Zhang, L.; Zhou, K.; Ye, X.; Zhang, J.; Xie, A.; Chen, L.; Kang, J.X.; Cai, C. Simultaneous determination of global DNA methylation and hydroxymethylation levels by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J. Biomol. Screen., 2012, 17, 877-884.
Arnold, M.E.; Booth, B.; King, L.; Ray, C. Workshop Report: Crystal city VI-Bioanalytical method validation for biomarkers. AAPS J., 2016, 18, 1366-1372.
Schley, P.D.; Brindley, D.N.; Field, C.J. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J. Nutr., 2007, 137, 548-553.
Smith, W.L. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol., 2005, 17, 174-182.
Vanamala, J.; Glagolenko, A.; Yang, P.; Carroll, R.J.; Murphy, M.E.; Newman, R.A.; Ford, J.R.; Braby, L.A.; Chapkin, R.S.; Turner, N.D.; Lupton, J.R. Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3. Carcinogenesis, 2008, 29, 790-796.
Ng, Y.; Barhoumi, R.; Tjalkens, R.B.; Fan, Y.Y.; Kolar, S.; Wang, N.; Lupton, J.R.; Chapkin, R.S. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis, 2005, 26, 1914-1921.
Seki, H.; Tani, Y.; Arita, M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat., 2009, 89, 126-130.
Arita, M.; Clish, C.B.; Serhan, C.N. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem. Biophys. Res. Commun., 2005, 338, 149-157.
Kudo, Y.; Tateishi, K.; Yamamoto, K.; Yamamoto, S.; Asaoka, Y.; Ijichi, H.; Nagae, G.; Yoshida, H.; Aburatani, H.; Koike, K. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci., 2012, 103, 670-676.
Coulter, J.B.; O’Driscoll, C.M.; Bressler, J.P. Hydroquinone increases 5-hydroxymethylcytosine formation through ten eleven translocation 1 (TET1) 5-methylcytosine dioxygenase. J. Biol. Chem., 2013, 288, 28792-28800.
Chia, N.; Wang, L.; Lu, X.; Senut, M.C.; Brenner, C.; Ruden, D.M. Hypothesis: Environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics, 2011, 6, 853-856.
Fu, H.L.; Ma, Y.; Lu, L.G.; Hou, P.; Li, B.J.; Jin, W.L.; Cui, D.X. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J. Biomed. Nanotechnol., 2014, 10, 1217-1230.
Muller, T.; Gessi, M.; Waha, A.; Isselstein, L.J.; Luxen, D.; Freihoff, D.; Freihoff, J.; Becker, A.; Simon, M.; Hammes, J.; Denkhaus, D.; Zur, M.A.; Pietsch, T.; Waha, A. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol., 2012, 181, 675-683.
Hsu, C.H.; Peng, K.L.; Kang, M.L.; Chen, Y.R.; Yang, Y.C.; Tsai, C.H.; Chu, C.S.; Jeng, Y.M.; Chen, Y.T.; Lin, F.M.; Huang, H.D.; Lu, Y.Y.; Teng, Y.C.; Lin, S.T.; Lin, R.K.; Tang, F.M.; Lee, S.B.; Hsu, H.M.; Yu, J.C.; Hsiao, P.W.; Juan, L.J. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep., 2012, 2, 568-579.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 18 October, 2018
Page: [330 - 336]
Pages: 7
DOI: 10.2174/1871520618666181018143026
Price: $65

Article Metrics

PDF: 33